{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:41:05Z","timestamp":1790905265118,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Blood-based biomarkers (BBMs) are clinically available to aid in the diagnosis of Alzheimer disease (AD) and AD-related dementias (ADRD), but their association with cognition among older adults with specific chronic conditions has not been examined.<\/jats:p><\/jats:sec>Objective<\/jats:title>To longitudinally examine associations between baseline AD and ADRD BBMs and change in BBMs with cognition among participants with type 2 diabetes (T2D) and overweight or obesity.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>The Look AHEAD (Action for Health in Diabetes) study was a clinical trial of older adults with T2D and overweight or obesity randomized to a 10-year intensive lifestyle intervention for weight loss or a diabetes support and education condition. Participants were recruited and followed up at 16 clinical sites across the US. Enrollment occurred from January 1, 2001, to December 31, 2004. The primary intervention spanned the first 4 years after participants\u2019 enrollment (January 1, 2008, to December 31, 2011). The clinical trial was stopped in September 2012 and was converted to an observational study. Blood samples were drawn at baseline and 8 to 12 years later. Cognitive assessments were performed from January 1, 2013, to December 31, 2014, and from January 1, 2018, to December 31, 2020. Data for the present cohort study were analyzed between January and August 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Baseline and 8- to 12-year change in plasma levels of amyloid-\u03b2 (A\u03b2)40<\/jats:sub>, A\u03b242<\/jats:sub>, A\u03b242\/40<\/jats:sub> ratio, phosphorylated tau 181 (pTau-181), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL).<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Cognitive composite z<\/jats:italic> score and adjudicated mild cognitive impairment or probable dementia.<\/jats:p><\/jats:sec>Results<\/jats:title>The mean (SD) baseline age of 758 participants was 61.5 (6.1) years, and 424 participants [55.9%] were female. Mean (SD) body mass index was 34.8 (5.3). Of the participants, 373 were randomized to diabetes support and education and 385 to intensive lifestyle intervention. Increasing baseline BBM levels were not associated with any cognitive composite z<\/jats:italic> score. Increasing levels of NfL (\u03b2\u2009=\u2009\u22120.032 [SE, 0.013]; P<\/jats:italic>\u2009=\u2009.01) and GFAP (\u03b2\u2009=\u2009\u22120.087 [SE, 0.025]; P<\/jats:italic>\u2009&amp;lt;\u2009.001), but not the A\u03b242\/40<\/jats:sub> ratio (\u03b2\u2009=\u20090.006 [SE, 0.040]; P<\/jats:italic>\u2009=\u2009.88) or pTau-181 (\u03b2\u2009=\u20090.026 [SE, 0.025]; P<\/jats:italic>\u2009=\u2009.31), were associated with worsening cognitive function and incident mild cognitive impairment or probable dementia. The intervention had no association with 8- to 12-year change in BBM levels.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this study of participants with T2D and overweight or obesity, increasing plasma NfL and GFAP levels over time, but not A\u03b242\/40<\/jats:sub> or pTau-181 levels, were associated with cognitive decline and incident cognitive impairment. These results suggest that plasma NfL and GFAP may be important biomarkers of cognitive change among this patient population.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.58149","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T16:32:23Z","timestamp":1738859543000},"page":"e2458149","source":"Crossref","is-referenced-by-count":33,"title":["Alzheimer Disease Blood Biomarkers and Cognition Among Individuals With Diabetes and Overweight or Obesity"],"prefix":"10.1001","volume":"8","author":[{"given":"Michelle M.","family":"Mielke","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joni K.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca H.","family":"Neiberg","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris P.","family":"Molina-Henry","sequence":"additional","affiliation":[{"name":"Winston-Salem State University, Winston-Salem, North Carolina"},{"name":"Alzheimer\u2019s Therapeutic Research Institute, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santica M.","family":"Marcovina","sequence":"additional","affiliation":[{"name":"Medpace Reference Laboratories, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen T.","family":"Carmichael","sequence":"additional","affiliation":[{"name":"Biomedical Imaging Center, Pennington Biomedical Research Center, Baton Rouge, Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Rapp","sequence":"additional","affiliation":[{"name":"Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina"},{"name":"Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie C.","family":"Sachs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Wake Forest University School of Medicine, Winston-Salem, North Carolina"},{"name":"Department of Internal Medicine, Division of Gerontology and Geriatric Medicine Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhong","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gerontology and Geriatric Medicine Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather M.","family":"Shappell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Luchsinger","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Espeland","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina"},{"name":"Department of Internal Medicine, Division of Gerontology and Geriatric Medicine Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Hayden","sequence":"additional","affiliation":[{"name":"Department of Social Sciences and Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"issue":"13","key":"zoi241628r1","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia.","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"zoi241628r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102290","article-title":"A critical appraisal of blood-based biomarkers for Alzheimer\u2019s disease.","volume":"96","author":"Lista","year":"2024","journal-title":"Ageing Res Rev"},{"issue":"1","key":"zoi241628r3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation.","volume":"21","author":"Teunissen","year":"2022","journal-title":"Lancet Neurol"},{"issue":"3","key":"zoi241628r4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia.","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"zoi241628r5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"zoi241628r6","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community.","volume":"28","author":"Mielke","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"zoi241628r7","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography.","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"7691","key":"zoi241628r8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u00df biomarkers for Alzheimer\u2019s disease.","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"issue":"8","key":"zoi241628r9","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u00df concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis.","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi241628r10","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders.","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"zoi241628r11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease.","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurol"},{"issue":"3","key":"zoi241628r12","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1212\/WNL.0000000000007767","article-title":"Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures.","volume":"93","author":"Mielke","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"zoi241628r13","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/alz.13560","article-title":"Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: results from the Ontario Neurodegenerative Disease Research Initiative.","volume":"20","author":"Sanchez","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi241628r14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41582-024-00989-1","article-title":"Alzheimer disease blood biomarkers: considerations for population-level use.","volume":"20","author":"Mielke","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"zoi241628r15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.19672","article-title":"Variation in population attributable fraction of dementia associated with potentially modifiable risk factors by race and ethnicity in the US.","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi241628r16","first-page":"1","article-title":"Association between modifiable risk factors and levels of blood-based biomarkers of Alzheimer\u2019s and related dementias in the Look AHEAD cohort.","volume":"13","author":"Hayden","year":"2024","journal-title":"JAR Life"},{"issue":"5","key":"zoi241628r18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0197-2456(03)00064-3","article-title":"Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.","volume":"24","author":"Ryan","year":"2003","journal-title":"Control Clin Trials"},{"issue":"2","key":"zoi241628r19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi241628r20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/oby.2006.84","article-title":"The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it.","volume":"14","author":"Wadden","year":"2006","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"zoi241628r21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1177\/1740774511405858","article-title":"The development and description of the comparison group in the Look AHEAD trial.","volume":"8","author":"Wesche-Thobaben","year":"2011","journal-title":"Clin Trials"},{"issue":"5","key":"zoi241628r22","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1111\/jgs.14692","article-title":"Effect of a long-term intensive lifestyle intervention on cognitive function: action for health in diabetes study.","volume":"65","author":"Rapp","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"zoi241628r25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions.","volume":"18","author":"Stroop","year":"1935","journal-title":"J Exp Psychol"},{"issue":"3","key":"zoi241628r26","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2466\/pms.1958.8.3.271","article-title":"Validity of the trail making test as an indicator of organic brain damage.","volume":"8","author":"Reitan","year":"2016","journal-title":"Percept Mot Skills"},{"issue":"8","key":"zoi241628r27","first-page":"314","article-title":"The Modified Mini-Mental State (3MS) examination.","volume":"48","author":"Teng","year":"1987","journal-title":"J Clin Psychiatry"},{"issue":"21","key":"zoi241628r28","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1212\/WNL.0000000000003955","article-title":"Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment.","volume":"88","author":"Espeland","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"zoi241628r29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community.","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"key":"zoi241628r30","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2147\/CIA.S65381","article-title":"The LIFE Cognition Study: design and baseline characteristics.","volume":"9","author":"Sink","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"12","key":"zoi241628r31","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/oby.2003.201","article-title":"Obesity modulates the association among APOE genotype, insulin, and glucose in men.","volume":"11","author":"Elosua","year":"2003","journal-title":"Obes Res"},{"issue":"1","key":"zoi241628r32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/brain\/awac354","article-title":"Diabetes and hypertension are related to amyloid-beta burden in the population-based Rotterdam Study.","volume":"146","author":"van Arendonk","year":"2023","journal-title":"Brain"},{"issue":"14","key":"zoi241628r33","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1001\/jama.2017.3090","article-title":"Association between midlife vascular risk factors and estimated brain amyloid deposition.","volume":"317","author":"Gottesman","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"zoi241628r34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2967\/jnumed.113.132647","article-title":"Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation.","volume":"55","author":"Roberts","year":"2014","journal-title":"J Nucl Med"},{"issue":"8","key":"zoi241628r35","doi-asserted-by":"publisher","first-page":"e836","DOI":"10.1212\/WNL.0000000000012440","article-title":"Diabetes mellitus and cognition: pathway analysis in the MEMENTO cohort.","volume":"97","author":"Frison","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"zoi241628r36","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.2337\/dc24-0229","article-title":"Plasma biomarkers of brain injury and their association with brain MRI and cognition in type 1 diabetes.","volume":"47","author":"Karger","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"zoi241628r37","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1038\/s41467-021-23620-z","article-title":"A multicentre validation study of the diagnostic value of plasma neurofilament light.","volume":"12","author":"Ashton","year":"2021","journal-title":"Nat Commun"},{"issue":"3","key":"zoi241628r38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/psyg.12819","article-title":"Plasma NfL is associated with mild cognitive decline in patients with diabetes.","volume":"22","author":"Marutani","year":"2022","journal-title":"Psychogeriatrics"},{"issue":"5","key":"zoi241628r39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","article-title":"Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads.","volume":"15","author":"Salvad\u00f3","year":"2023","journal-title":"EMBO Mol Med"},{"issue":"10","key":"zoi241628r40","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/acn3.51652","article-title":"A population-based meta-analysis of circulating GFAP for cognition and dementia risk.","volume":"9","author":"Gonzales","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"zoi241628r23","author":"Rey","year":"1958"},{"key":"zoi241628r24","author":"Wechsler","year":"1997"},{"key":"zoi241628r17","unstructured":"ClinicalTrials.gov. Look AHEAD: Action for Health in Diabetes (LookAHEAD). NCT00017953. Accessed December 12, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00017953"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829913\/mielke_2025_oi_241628_1738174134.05771.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T16:32:27Z","timestamp":1738859547000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.58149","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]}}}